GlassScriptPhysician profile
Kristen E Boyle
NPI 1295349702
$1,520.60
in general payments reported to CMS, 2019-2025
13 companies · $414 in 2025
The $414 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $146 · 2022: $130 · 2023: $321 · 2024: $510 · 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $717 · Education: $291 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $716.83 |
| Education | $291.36 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $236.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $334.93 | 2021-2024 | |
| Teleflex LLC | $277.74 | 2022-2025 | Arrow |
| Astrazeneca Pharmaceuticals LP | $236.84 | 2024 | |
| Jazz Pharmaceuticals INC. | $139.64 | 2025 | |
| Lilly USA, LLC | $116.42 | 2023 | Retevmo, Verzenio, Jaypirca |
| Sanofi-Aventis U.S. LLC | $114.65 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $88.74 | 2024-2025 | Opdualag, Opdivo |
| Coherus Oncology, INC. | $84.99 | 2021 | |
| Pfizer INC. | $46.52 | 2024-2025 | |
| Genentech USA, INC. | $24.56 | 2025 | Polivy |
| Kite Pharma, INC. | $22.69 | 2025 | Yescarta |
| Glaxosmithkline, LLC. | $18.88 | 2025 | Ojjaara, Jemperli |
| Servier Pharmaceuticals LLC | $14.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristen Boyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.